Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More